Home
Edit 
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit!
If you are interested in the 2026 event, please get in touch at info@hansonwade.com
Advancing FcRN, FcyR, & IgG Therapeutics
Full Event Guide Register Interest Partner
Evaluating FcRN, FcyR, & IgG Biology for Targeting & Antibody Engineering to Advance Molecular Development, Clinical Utility, & Novel Therapeutic Applications
The landscape of Fc-mediated therapies is undergoing a radical transformation, driven by precise Fc-receptor targeting and antibody domain modification to unlock new levels of efficacy and safety for unprecedented therapeutic potential in oncology and autoimmune disease treatment. The 5th Fc-Mediated Function Summit is the essential destination for experts driving innovation in Fc-receptor targeting and antibody domain modification.
This year, we’re evaluating the cutting-edge of Fc biology and engineering, diving deep into the game-changing potential of novel Fc modifications, bispecific formats, and targeted effector functions to revolutionize the treatment of cancer, autoimmune diseases, and beyond. Hear from the titans of the pharmaceutical industry, including AbbVie, Novartis, and UCB as well as innovative biotechs including Seismic Therapeutics, Paradigm Immunotherapies, and many more – as they share their groundbreaking research and strategies for developing more effective, safer, and long-lasting fc-mediated solutions. The therapeutic potential of Fc-mediated functions is surging following last year’s wave in FDA approvals from BeiGene’s Tevimbra to Genetech’s approval of Piasky, and the pressure is on to continue this success and develop best-in-class treatments.
Don’t miss this pivotal opportunity to network with 50+ leading scientists and drug development experts in the field of Fc-Mediated Function, forge crucial collaborations, and be part of the solution. The future of antibody therapeutics is being written now – be a part of it!
DOWNLOAD THE 2025 EVENT GUIDE HERE
2025 World-Class Speaker Faculty Included:
David Humphreys
Exec Dir
UCB
Julian Chandler M.Sc.
Associate Director
Alexion, AstraZeneca Rare Disease
Jyothsna Visweswaraiah
Senior Director, Biotherapeutics, Drug Creation
Seismic Therapeutic
Richard Blumberg
Professor of Medicine
Harvard University
Sally Ward
Director of Translational Immunology
University of Southampton
Vladimir Bobkov
Principal Scientist – Discovery
Argenx
View All Speakers “The conference was efficient and extremely focused on relevant content and high-quality speakers.
The agenda and timing were well-planned, with enough time for questions, but not so much that discussions
ever dragged on.”
Scientist, Eli Lilly
Previously Attending Companies Include:
Official 2025 Partners
